In 2009 Novartis and MMV launched the first high-quality artemisinin combination therapy (ACT) formulated especially for children – Coartem®Dispersible (artemether-lumefantrine). Since then, 350 million treatments of this life-saving medicine have been delivered to 50 malaria-endemic countries.
Children
MMV has long recognized that developing better medicines for children helps address the most vulnerable patient population at greatest risk of dying from malaria. MMV and partners are developing and improving access to child-friendly formulations of existing antimalarials for treatment (artemisinin-based combination therapies; ACTs), and chemoprevention (sulfadoxine-pyrimethamine + amodiaquine; SP+AQ), as well as developing next-generation medicines for children in parallel with adult formulations.
